6185
Sign in
Cansino Biologics Inc.
Save
9.83B
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
Similar securities
Based on sector and market capitalization
Report issue